71 results
Keyword Cyramza Remove keyword
-
List item
Opinion/decision on a Paediatric investigation plan (PIP): Cyramza, Ramucirumab
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Oncology
PIP number: EMEA-002074-PIP01-16, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Concentrate for solution for infusion
Decision date: 04/10/2017, Last updated: 12/02/2018, Compliance check: XInvented name Cyramza Active substance Ramucirumab … specific waiver for ramucirumab (Cyramza), (EMEA-002074-PIP01-16 … specific waiver for ramucirumab (Cyramza), (EMEA-002074-PIP01-16 … -
List item
Human medicine European public assessment report (EPAR): Cyramza (updated)
Ramucirumab, Stomach Neoplasms
Date of authorisation: 19/12/2014, Revision: 16, Authorised, Last updated: 28/11/2023Cyramza Cancer Neoplasms Digestive … horised ramucirumab Overview Cyramza is a cancer medicine used … alpha fetoprotein (AFP). Cyramza is for use in cancers that … -
List item
Orphan designation: Ramucirumab for: Treatment of gastric cancer
Date of designation: 04/07/2012, Withdrawn, Last updated: 19/01/2016been authorised in the EU as Cyramza since 19 December 2014. Expand … Update: ramucirumab (Cyramza) has been authorised in the … EU since 19 December 2014. Cyramza monotherapy is indicated … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2019
CHMP, Last updated: 13/12/2019Cyramza … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2019
CHMP, Last updated: 28/06/2019Cyramza … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 December 2015
CHMP, Last updated: 18/12/2015Cyramza … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 September 2014
CHMP, Last updated: 26/09/2014Cyramza … -
List item
Human medicine European public assessment report (EPAR): Lumykras (updated)
sotorasib, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 06/01/2022,
, 
, Revision: 2, Authorised, Last updated: 20/11/2023
-
List item
Press release: Record number of medicines for rare diseases recommended for approval in 2014
Last updated: 09/01/2015Lynparza, Imbruvica, Gazyvaro and Cyramza target rare cancers that … Lynparza, Imbruvica, Gazyvaro and Cyramza target rare cancers that … -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 28 November - 1 December 2022
European Medicines Agency, Amsterdam, the Netherlands, from 28/11/2022 to 01/12/2022, Last updated: 03/04/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 March 2022
European Medicines Agency, Amsterdam, the Netherlands, from 07/03/2022 to 10/03/2022, Last updated: 22/11/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 21-24 March 2022
European Medicines Agency, Amsterdam, the Netherlands, from 21/03/2022 to 24/03/2022, Last updated: 12/08/2022 -
List item
CHMP: Agendas, minutes and highlights (updated)
Last updated: 10/11/2023 -
List item
Committee for Medicinal Products for Human Use (CHMP): 20-23 February 2023
European Medicines Agency, Amsterdam, the Netherlands, from 20/02/2023 to 23/02/2023, Last updated: 24/04/2023 -
List item
PRIME: priority medicines
Last updated: 03/11/2023 -
List item
Committee for Medicinal Products for Human Use (CHMP): 23-26 January 2023
European Medicines Agency, Amsterdam, the Netherlands, from 23/01/2023 to 26/01/2023, Last updated: 14/04/2023 -
List item
Committee for Medicinal Products for Human Use (CHMP): 24-27 January 2022
European Medicines Agency, Amsterdam, the Netherlands, from 24/01/2022 to 27/01/2022, Last updated: 16/03/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 21-24 September 2015
European Medicines Agency, London, UK, from 21/09/2015 to 24/09/2015, Last updated: 03/01/2014 -
List item
Committee for Medicinal Products for Human Use (CHMP): 14-17 December 2015
European Medicines Agency, London, UK, from 14/12/2015 to 17/12/2015, Last updated: 03/01/2014 -
List item
Committee for Medicinal Products for Human Use (CHMP): 8-11 November 2021
Online, from 08/11/2021 to 11/11/2021, Last updated: 20/01/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 18-21 May 2015
European Medicines Agency, London, UK, from 18/05/2015 to 21/05/2015, Last updated: 03/01/2014 -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 04/12/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 8-11 June 2015
European Medicines Agency, London, UK, from 08/06/2015 to 11/06/2015, Last updated: 13/03/2014 -
List item
Committee for Medicinal Products for Human Use (CHMP): 22-25 June 2015
European Medicines Agency, London, UK, from 22/06/2015 to 25/06/2015, Last updated: 03/01/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 September 2015
European Medicines Agency, London, UK, from 07/09/2015 to 10/09/2015, Last updated: 13/03/2014